Supernus Pharmaceuticals, Inc.
NASDAQ:SUPN
31.11 (USD) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 607.521 | 667.238 | 579.775 | 520.397 | 392.755 | 408.897 | 302.238 | 215.003 | 144.427 | 122.045 | 12.019 | 1.48 | 0.803 | 0.106 | 37.925 | 8.889 | 4.233 |
| Cost of Revenue
| 168.638 | 87.221 | 75.061 | 52.459 | 16.66 | 15.356 | 15.215 | 11.986 | 8.423 | 5.758 | 1.104 | 0 | 0 | -13.404 | -8.588 | 0 | 0 |
| Gross Profit
| 438.883 | 580.017 | 504.714 | 467.938 | 376.095 | 393.541 | 287.023 | 203.017 | 136.004 | 116.287 | 10.915 | 1.48 | 0.803 | 13.51 | 46.513 | 8.889 | 4.233 |
| Gross Profit Ratio
| 0.722 | 0.869 | 0.871 | 0.899 | 0.958 | 0.962 | 0.95 | 0.944 | 0.942 | 0.953 | 0.908 | 1 | 1 | 127.453 | 1.226 | 1 | 1 |
| Reseach & Development Expenses
| 89.119 | 74.552 | 90.467 | 75.961 | 69.099 | 89.209 | 49.577 | 42.791 | 29.135 | 19.586 | 17.245 | 23.517 | 30.627 | 35.149 | 29.26 | 30.463 | 19.269 |
| General & Administrative Expenses
| 107.175 | 109.433 | 105.05 | 65.924 | 117.625 | 116.588 | 104.105 | 84.11 | 69.904 | 57.671 | 40.99 | 14.332 | 0 | 5.08 | 4.649 | 4.287 | 0 |
| Selling & Marketing Expenses
| 229.186 | 267.788 | 199.709 | 134.753 | 40.8 | 43.3 | 33.8 | 21.9 | 19.3 | 14.8 | 14.6 | 5.8 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 336.361 | 377.221 | 304.759 | 200.677 | 158.425 | 159.888 | 137.905 | 106.01 | 89.204 | 72.471 | 55.59 | 20.132 | 7.928 | 5.08 | 4.649 | 4.287 | 4.012 |
| Other Expenses
| 0 | 82.63 | 29.989 | 15.702 | 0 | 0 | 0 | -0.015 | 0.038 | 0.039 | 0.101 | -0.66 | 0.117 | 0.542 | 0 | 0 | 0 |
| Operating Expenses
| 425.48 | 534.403 | 425.215 | 292.34 | 227.524 | 249.097 | 187.482 | 148.801 | 118.339 | 92.057 | 72.835 | 43.649 | 38.555 | 40.229 | 33.909 | 34.75 | 23.28 |
| Operating Income
| 13.403 | 67.303 | 86.029 | 173.698 | 148.571 | 144.444 | 99.541 | 54.216 | 17.665 | 24.23 | -61.92 | -42.169 | -37.752 | -40.123 | 4.016 | -25.861 | -19.047 |
| Operating Income Ratio
| 0.022 | 0.101 | 0.148 | 0.334 | 0.378 | 0.353 | 0.329 | 0.252 | 0.122 | 0.199 | -5.152 | -28.493 | -47.014 | -378.519 | 0.106 | -2.909 | -4.499 |
| Total Other Income Expenses Net
| -10.634 | -6.56 | -12.854 | -5.05 | -1.084 | -4.268 | -0.219 | -0.238 | -2.107 | 0.217 | -22.904 | -0.66 | 0.117 | 0.542 | 0.122 | -7.621 | 1.773 |
| Income Before Tax
| 2.769 | 60.743 | 73.175 | 168.648 | 147.487 | 140.176 | 100.618 | 50.369 | 14.972 | 19.871 | -92.273 | -46.284 | -39.47 | -39.474 | 4.138 | -33.482 | -17.274 |
| Income Before Tax Ratio
| 0.005 | 0.091 | 0.126 | 0.324 | 0.376 | 0.343 | 0.333 | 0.234 | 0.104 | 0.163 | -7.677 | -31.273 | -49.153 | -372.396 | 0.109 | -3.767 | -4.08 |
| Income Tax Expense
| 1.453 | 0.032 | 19.751 | 41.698 | 34.431 | 29.183 | 43.334 | -40.852 | 0.956 | 4.035 | 7.107 | 1.143 | -16.245 | -0.399 | 3.8 | 1.057 | 1.773 |
| Net Income
| 1.316 | 60.711 | 53.424 | 126.95 | 113.056 | 110.993 | 57.284 | 91.221 | 14.016 | 19.871 | -92.273 | -46.284 | 56.003 | -38.463 | 0.46 | -33.482 | -17.274 |
| Net Income Ratio
| 0.002 | 0.091 | 0.092 | 0.244 | 0.288 | 0.271 | 0.19 | 0.424 | 0.097 | 0.163 | -7.677 | -31.273 | 69.742 | -362.858 | 0.012 | -3.767 | -4.08 |
| EPS
| 0.024 | 1.13 | 1.01 | 2.41 | 2.16 | 2.13 | 1.13 | 1.84 | 0.29 | 0.47 | -2.9 | -2.65 | 3.64 | -2.78 | -0.21 | -2.42 | -1.25 |
| EPS Diluted
| 0.024 | 1.04 | 0.98 | 2.36 | 2.1 | 2.05 | 1.08 | 1.76 | 0.28 | 0.32 | -2.9 | -2.65 | 3.64 | -2.78 | -0.21 | -2.42 | -1.25 |
| EBITDA
| 98.262 | 149.933 | 120.057 | 210.004 | 170.194 | 158.287 | 102.405 | 55.683 | 18.346 | 24.617 | -61.52 | -42.709 | -36.725 | -38.286 | 5.21 | -23.689 | -16.342 |
| EBITDA Ratio
| 0.162 | 0.225 | 0.207 | 0.404 | 0.433 | 0.387 | 0.339 | 0.259 | 0.127 | 0.202 | -5.119 | -28.857 | -45.735 | -361.189 | 0.137 | -2.665 | -3.86 |